Coreleader has invited MD and PhD Tzu-Hsin Lin who received his doctoral degree from Boston University and currently serves as the head trauma surgeon in the teaching hospital of National Taiwan University, to present his trial result in ECTES 2015 on May 10. The rial was conducted by MD. Lin with the help of his lab staff in the teaching hospital during March and April. The trial was in full compliance with the US army's protocol. His trial finding proves that HEMO-bandage has a double survival rate than that of Combat Gauze, the current personal first aid item used by US army.

After his presentation, the question from the floor was coming from Dr. Reva, a Russian Medic, who reported his findings from the two trials he did with the HEMO-bandage in his hospital. What a pleasant surprise to us.  He was fully impressed by its haemostatic efficacy. Other than his positive comment to the presentation, he questioned what the secret the HEMO-bandage has to achieve the haemostasis so effectively comparing with other chitosan based haemostatic agents as he concluded his own studies in Russia. Dr. Reva received his samples from us in August, 2014.  He had tested the  two packs separately, one on a goat with an artificial gun shot wound and one on a kid that was rushed to ER from accident.  His supportive statement to our HEMO-bandage reinforces our confidence on pursuing the FDA approvals.
發表日期:2015-05-18